ipamorelin clinical trials safety adverse effects CJC-1295 FDA Status: 2026 Compounding Guide COVID-19 Clinical Trials Safety Side

providing medical services, namely, counseling and advising patients regarding surgical care, medical care, health care, and surgical and medical products, devices, apparatus, appliances, and instruments pertaining to gastrointestinal surgery

Additionally, low-dose berberine protected PC12 cells from 6-hydroxydopamine (6-OHDA, Parkinsons disease-related neurotoxin)-induced cytotoxicity and apoptosis, whereas high-dose berberine showed no neuroprotective activity

& Ando, M

Side Effects & Safety No lethal dose found -- toxicology studies couldn't establish an LD50 (Sikiric et al., 2006) No organ toxicity in chronic dosing No hormonal effects -- doesn't affect testosterone, estrogen, cortisol, or GH Mild nausea -- mostly with oral dosing Brief lightheadedness -- occasionally after injection Injection site redness -- standard for SC peptides Angiogenesis concern -- promotes new blood vessel growth, which raises a theoretical question about existing tumors